Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 30 articles: HTML format

Single Articles

April 2024
1. EARL HM
   Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
   Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
   PubMed    
   
   
   
2. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   PubMed     Abstract available
   
   
   March 2024
3. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
   Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
   Lancet. 2024;403:1240.
   PubMed    
   
   
   
4. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
   Benefits and risks of anthracyclines in early-stage breast cancer.
   Lancet. 2024;403:1239-1240.
   PubMed    
   
   
   
5. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
   Managing menopause after cancer.
   Lancet. 2024;403:984-996.
   PubMed     Abstract available
   
   
   December 2023
6. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
   Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
   Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
   PubMed     Abstract available
   
   
   
7. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
   Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
   Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
   PubMed     Abstract available
   
   
   
8. BRAUNSTEIN LZ
   Optimising adjuvant breast radiotherapy via preoperative imaging.
   Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
   PubMed    
   
   
   November 2023
9. 
   Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
   Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
   PubMed     Abstract available
   
   
   
10. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    PubMed    
    
    
    
11. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    PubMed     Abstract available
    
    
    
12. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    PubMed     Abstract available
    
    
    
13. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    PubMed     Abstract available
    
    
    August 2023
14. LOIBL S, Holtschmidt J
    Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?
    Lancet. 2023 Aug 23:S0140-6736(23)01783-X. doi: 10.1016/S0140-6736(23)01783.
    PubMed    
    
    
    
15. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    PubMed     Abstract available
    
    
    June 2023
16. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    PubMed     Abstract available
    
    
    April 2023
17. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    PubMed     Abstract available
    
    
    
18. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    PubMed    
    
    
    
19. 
    Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    PubMed     Abstract available
    
    
    
20. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    PubMed    
    
    
    January 2023
21. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    PubMed    
    
    
    
22. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    PubMed    
    
    
    December 2022
23. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    PubMed    
    
    
    
24. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    PubMed     Abstract available
    
    
    November 2022
25. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    PubMed     Abstract available
    
    
    
26. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    PubMed    
    
    
    August 2022
27. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    PubMed     Abstract available
    
    
    
28. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    PubMed    
    
    
    February 2022
29. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
    PubMed    
    
    
    January 2021
30. 
    Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.